These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32081246)

  • 21. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 23. Strut Coverage After Paclitaxel-Eluting Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Fukunaga M; Nishimura M; Horimatsu T; Saita T; Sumiyoshi A; Tamaru H; Imanaka T; Shibuya M; Naito Y; Masuyama T; Ishihara M
    JACC Cardiovasc Imaging; 2016 Jun; 9(6):753-5. PubMed ID: 26298069
    [No Abstract]   [Full Text] [Related]  

  • 24. Commentary: intravascular ultrasound for femoropopliteal stenting: can it predict outcomes with current-generation stents?
    Foley TR; Armstrong EJ
    J Endovasc Ther; 2015 Jun; 22(3):350-1. PubMed ID: 25904483
    [No Abstract]   [Full Text] [Related]  

  • 25. Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries.
    Sakamoto A; Torii S; Jinnouchi H; Fuller D; Cornelissen A; Sato Y; Kuntz S; Mori M; Kawakami R; Kawai K; Fernandez R; Paek KH; Gadhoke N; Guo L; Kolodgie FD; Young B; Ragheb A; Virmani R; Finn AV
    J Vasc Interv Radiol; 2021 Jun; 32(6):792-801.e5. PubMed ID: 33677117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents.
    Hoyt T; Feldman MD; Okutucu S; Lendel V; Marmagkiolis K; McIntosh V; Ates I; Kose G; Mego D; Paixao A; Iliescu C; Park J; Shaar M; Avci R; McElroy A; Dijkstra J; Milner TE; Cilingiroglu M
    Cardiovasc Revasc Med; 2020 Jan; 21(1):101-107. PubMed ID: 31395436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Femoral-popliteal peripheral artery disease: From symptom presentation to management and treatment controversies.
    Krawisz AK; Raja A; Secemsky EA
    Prog Cardiovasc Dis; 2021; 65():15-22. PubMed ID: 33592208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 31. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
    Buszman PP; Nowakowski P; Milewski K; Orlik B; Żurakowski A; Ludyga T; Polczyk F; Dębiński M; Jelonek M; Kachel M; Gąsior M; Granada JF; Kiesz RS; Buszman PE
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2436-2438. PubMed ID: 30522679
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination therapy of heparin-bonded covered stent and bare-nitinol stent assessed by intravascular ultrasound.
    Katsuki T; Tomoi Y; Yamaji K; Soga Y; Imada K; Ito N; Hiramori S; Ando K
    Heart Vessels; 2020 Nov; 35(11):1502-1509. PubMed ID: 32462463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
    Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Influencing in-Stent Occlusion after Femoropopliteal Artery Stent Placement with Intravascular Ultrasound Evaluation.
    Kurata N; Iida O; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Mano T
    J Vasc Interv Radiol; 2020 Feb; 31(2):213-220. PubMed ID: 31883937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
    Zeller T; Brodmann M; Micari A; Keirse K; Peeters P; Tepe G; Scheinert D; Jaff MR; Rocha-Singh KJ; Li P; Schmahl R; Ansel GM;
    Circ Cardiovasc Interv; 2019 Jan; 12(1):e007730. PubMed ID: 30630355
    [No Abstract]   [Full Text] [Related]  

  • 40. Self-expanding nitinol stents of high versus low chronic outward force in de novo femoropopliteal occlusive arterial lesions (BIOFLEX-COF trial): study protocol for a randomized controlled trial.
    Wressnegger A; Kaider A; Funovics MA
    Trials; 2017 Dec; 18(1):594. PubMed ID: 29237489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.